NCT05620264 (VICTORIA) is a clinical trial of Tear Sample Probe in Keratitis Bacterial, sponsored by Johannes Kepler University of Linz.

Who is sponsoring NCT05620264?

NCT05620264 is sponsored by Johannes Kepler University of Linz.

What drugs are being tested in NCT05620264?

Interventions in NCT05620264: Tear Sample Probe.

What condition does NCT05620264 study?

NCT05620264 studies Keratitis Bacterial, Keratitis Fungal.

Is NCT05620264 still recruiting?

NCT05620264 is currently status unknown. Last updated 13 October 2023.

Last reviewed 2023-10-13 · How we verify

NCT05620264: VICTORIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of Interleukins and Other Cytokines Together With OCT Imaging for Rapid Infectious Keratitis Assessment

Status unknown Last updated 13 October 2023

What this trial tests

trial testing Tear Sample Probe in Keratitis Bacterial in 392 participants. Status unknown.

Timeline

21 March 2022

Primary endpoint
30 April 2024

15 October 2024

Quick facts

Lead sponsor	Johannes Kepler University of Linz
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	392
Start date	21 March 2022
Primary completion	30 April 2024
Estimated completion	15 October 2024
Sites	1 location across Austria

Drugs / interventions tested

Tear Sample Probe

Conditions studied

Keratitis Bacterial — all drugs for Keratitis Bacterial →
Keratitis Fungal — all drugs for Keratitis Fungal →

Sponsor

Johannes Kepler University of Linz

Who can join

Adults 18 to 119, any sex, with Keratitis Bacterial or Keratitis Fungal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As conventional corneal scraping with bacterial culturing has several disadvantages such as long duration until diagnosis, invasiveness and lacks alternatives, there is demand for a novel non-invasive, rapid test in keratitis management. First aim of this study will be to evaluate the influence of TNF-alpha on Gram+ and Gram- bacteria causing keratitis. Second aim of this study will be to develop an algorithm, that should help to distinguish between different pathogens causing keratitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Johannes Kepler University of Linz trials

Trials by the same sponsor.

NCT07202767 — Intraocular Lens Calculation Using Artificial Intelligence · not yet recruiting
NCT07210372 — Axial Stability in Short and Long Eyes After Cataract Surgery · completed
NCT06595693 — Tilt Prediction of Clareon Intraocular Lens · completed
NCT05719532 — Core Strength and Coordinative Skills · unknown
NCT05769543 — WATSU and Body Awareness · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05620264 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johannes Kepler University of Linz
Last refreshed: 13 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05620264.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing